Mandate

Vinge advises Ultimovacs AS on its acquisition of the immunotherapy business of Immuneed AB

September 03, 2018 M&A

Vinge together with the Norwegian law firm Schjodt advises the Norwegian pharmaceuticals company Ultimovacs AS in connection with its acquisition of the immunotherpay business of the Uppsala based company Immuneed AB.

The business focuses on the development of vaccine for the treatment and potential prevention of cancer.

Vinge's team consisted primarily of the partner Jonas Johansson and the associates Carl Sander and Fredric Reismüller.

Related

Vinge has advised private equity firm Stirling Square Capital Partners

Vinge has advised private equity firm Stirling Square Capital Partners in connection with its acquisition of a majority stake in Infobric, a leading provider of software solutions for the construction industry, from Summa Equity.
September 22, 2023

Vinge advises Stendörren in connection with issuance of green notes and tender offer

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of senior unsecured green notes in an amount of SEK 500 million (within a framework of SEK 600 million) and its parallel tender offer in respect of its previously issued notes due 2024.
September 21, 2023

Vinge has advised Elektroskandia in connection with its majority investment in Aprilice

Vinge has advised Elektroskandia (a Sonepar company) in connection with its acquisition of 70% of the shares in Aprilice, one of the leading solar energy platforms in Northern Europe.
September 20, 2023